Filings/ZYDUSLIFE/IR

ZYDUS LIFESCIENCES LIMITED IR

press release

Sentynl Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) and BridgeBio Pharma Announce Asset Purchase Agreement for BridgeBio Pharmas NULIBRYTM (Fosdenopterin) - 08/03/2022

Source document

Issuer site
Loading document…
Sentynl Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) and BridgeBio Pharma Announce Asset Purchase Agreement for BridgeBio Pharmas NULIBRYTM (Fosdenopterin) - 08/03/2022 — ZYDUS LIFESCIENCES LIMITED